Back

Polyrizon enrolls first patient in U.S. NASARIX allergy-blocker study

Verifying
  • Polyrizon enrolled the first patient in a U.S. clinical study of NASARIX.
  • NASARIX is also identified as PL-14, an allergy blocker.
  • The enrollment marks a clinical development update for Polyrizon and PLRZ stock.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.